Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-24,240
Closed -$5.27M 8
2026
Q1
$5.27M Sell
24,240
-5,717
-19% -$1.27M 0.09% 87
2025
Q4
$6.84M Sell
29,957
-251
-0.8% -$57.2K 0.13% 71
2025
Q3
$6.99M Buy
30,208
+1,576
+6% +$321K 0.14% 66
2025
Q2
$5.31M Buy
28,632
+4,758
+20% +$884K 0.12% 79
2025
Q1
$5M Buy
23,874
+1,392
+6% +$271K 0.13% 71
2024
Q4
$4M Buy
22,482
+2,556
+13% +$470K 0.11% 83
2024
Q3
$3.94M Buy
+19,926
New +$3.72M 0.11% 83
2024
Q2
Sell
-19,748
Closed -$3.6M 106
2024
Q1
$3.6M Buy
+19,748
New +$3.4M 0.11% 85
2023
Q4
Sell
-21,105
Closed -$3.15M 95
2023
Q3
$3.15M Buy
21,105
+405
+2% +$59.5K 0.11% 91
2023
Q2
$2.79M Buy
20,700
+222
+1% +$32.6K 0.1% 97
2023
Q1
$3.26M Buy
20,478
+337
+2% +$51.5K 0.12% 86
2022
Q4
$3.25M Buy
20,141
+39
+0.2% +$5.98K 0.12% 92
2022
Q3
$2.7M Buy
20,102
+10
+0% +$1.44K 0.11% 89
2022
Q2
$3.08M Sell
20,092
-65
-0.3% -$9.93K 0.11% 90
2022
Q1
$3.27M Sell
20,157
-2,804
-12% -$407K 0.11% 93
2021
Q4
$3.11M Sell
22,961
-1,290
-5% -$152K 0.1% 98
2021
Q3
$2.62M Sell
24,251
-133
-0.5% -$15.2K 0.1% 106
2021
Q2
$2.75M Buy
24,384
+5,638
+30% +$635K 0.1% 106
2021
Q1
$2.03M Buy
18,746
+9,491
+103% +$1.02M 0.09% 113
2020
Q4
$992K Buy
9,255
+743
+9% +$71.4K 0.07% 98
2020
Q3
$746K Buy
8,512
+115
+1% +$10.8K 0.06% 103
2020
Q2
$824K Buy
8,397
+3,712
+79% +$327K 0.08% 79
2020
Q1
$357K Sell
4,685
-3,229
-41% -$275K 0.05% 125
2019
Q4
$701K Buy
7,914
+394
+5% +$32.7K 0.09% 106
2019
Q3
$569K Buy
+7,520
New +$516K 0.07% 138

Other funds holding ABBV

Evoke Wealth's ABBV Position: Q2 2026 in Review

Evoke Wealth sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 24,240 shares — an estimated $5.27M sold.

Evoke Wealth first reported a position in ABBV in Q3 2019 and held it in 25 quarters. The position peaked at $6.99M in Q3 2025. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Evoke Wealth reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
  • Evoke Wealth sold 24,240 AbbVie shares in Q2 2026, an estimated $5.27M.
  • Evoke Wealth first reported a position in AbbVie in Q3 2019 and held it in 25 quarters.
  • Evoke Wealth's AbbVie position peaked at $6.99M in Q3 2025.
  • 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.